Anterogen.Co.,Ltd. (KOSDAQ:065660)
South Korea · Delayed Price · Currency is KRW 15,410
+280 (1.85%)
Sep 1, 2026, 3:30 PM KST
Anterogen.Co.,Ltd. Financials Overview
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 8,369 | 7,536 | 6,933 | 6,500 | 6,591 | 8,122 |
Revenue Growth | 16.55% | 8.71% | 6.65% | -1.38% | -18.84% | 95.64% |
Gross Profit Gross Profit Growth | 2,850 | 2,656 | 2,518 | 2,612 | 2,503 | 3,837 |
Operating Income Operating Income Growth | -2,459 | -2,433 | -3,807 | -5,104 | -4,734 | -2,633 |
Net Income Net Income Growth | -1,617 | -1,374 | -2,293 | -2,841 | -6,837 | -553.98 |
Earnings Per Share EPS Growth | -161.73 | -137.64 | -236.00 | -292.00 | -706.00 | -59.00 |
EPS Growth | - | - | - | - | - | - |
| Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Cell Therapy Products and Rare Drugs Merchandise Cell Therapy Products and Rare Drugs Merchandise Growth | 6,419 | 5,356 | 5,934 | 5,832 | 3,452 |
Cell Therapy Products and Rare Drugs Product Cell Therapy Products and Rare Drugs Product Growth | 511.64 | 1,142 | 656.9 | 2,289 | 699.67 |
Other Other Growth | 1.91 | 1.95 | - | - | - |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 42,685 | 43,585 | 39,654 | 50,334 | 55,968 | 57,684 |
Total Debt Total Debt Growth | - | - | - | 9,740 | 12,711 | 11,770 |
Net Cash (Debt) Net Cash Growth | 42,685 | 43,585 | 39,654 | 40,593 | 43,257 | 45,913 |
Net Cash Growth | -2.64% | 9.91% | -2.31% | -6.16% | -5.79% | 18.74% |
Net Cash Per Share Net Cash Per Share Growth | 4269.08 | 4366.64 | 4081.52 | 4172.43 | 4466.72 | 4889.84 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | -1,114 | -1,020 | -860.38 | -1,988 | -1,975 | -3,045 |
Capital Expenditures CapEx Growth | -254.44 | -97.77 | -181.05 | -149.82 | -1,470 | -3,335 |
Free Cash Flow Free Cash Flow Growth | -1,368 | -1,118 | -1,041 | -2,138 | -3,446 | -6,380 |
Free Cash Flow Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 34.05% | 35.25% | 36.32% | 40.18% | 37.98% | 47.24% |
Operating Margin | -29.38% | -32.28% | -54.91% | -78.51% | -71.82% | -32.42% |
Pretax Margin | -15.98% | -14.52% | -33.07% | -43.70% | -103.93% | -6.82% |
Profit Margin | -19.32% | -18.23% | -33.07% | -43.70% | -103.73% | -6.82% |
FCF Margin | -16.35% | -14.83% | -15.02% | -32.89% | -52.28% | -78.56% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PS Ratio | 18.09 | 62.20 | 26.52 | 25.59 | 21.70 | 74.60 |